{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:16:56Z","timestamp":1784791016325,"version":"3.55.0"},"reference-count":76,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for identifying optimal therapies for the management of these conditions. Tirzepatide is a novel dual incretin receptor agonist (twincretin) that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The aim of this narrative review was to examine the impact of novel twincretins, focusing on tirzepatide, on the management of a wide spectrum of metabolic diseases. Data from preclinical and clinical trials have shown that twincretins significantly reduce blood glucose levels in T2D, and tirzepatide is the first agent of this class that has been approved for the management of T2D. Additionally, the beneficial impact of tirzepatide on weight reduction has been corroborated in several studies, showing that this agent can achieve substantial and sustained weight loss in obese patients with or without T2D. Data also suggest that tirzepatide could be a promising drug for hepatic steatosis reduction in individuals with NAFLD. The remarkable effects of tirzepatide on glycaemic control, weight loss and liver-related outcomes have posed new research questions that are likely to lead to further advancements in the treatment of T2D, obesity and related metabolic disorders.<\/jats:p>","DOI":"10.3390\/biomedicines11071875","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:42:46Z","timestamp":1688344966000},"page":"1875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-3064","authenticated-orcid":false,"given":"Alexandros Leonidas","family":"Liarakos","sequence":"first","affiliation":[{"name":"Centre for Diabetes and Endocrinology, Royal Berkshire NHS Foundation Trust, Reading RG1 5AN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-727X","authenticated-orcid":false,"given":"Chrysi","family":"Koliaki","sequence":"additional","affiliation":[{"name":"First Propaedeutic Department of Internal Medicine and Diabetes Center, Laiko General Hospital, Medical Faculty, National Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2021). IDF Diabetes Atlas, International Diabetes Federation. [10th ed.]. Available online: https:\/\/www.diabetesatlas.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health Effects of Overweight and Obesity in 195 Countries over 25 Years","volume":"377","author":"Afshin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cld.2015.01.012","article-title":"Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma","volume":"19","author":"Noureddin","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jceh.2019.07.008","article-title":"Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review","volume":"10","author":"Tariq","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s12325-020-01281-6","article-title":"Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review","volume":"37","author":"Parry","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10742484221146371","DOI":"10.1177\/10742484221146371","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity\/Metabolic Syndrome, Prediabetes\/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence","volume":"27","author":"Mikhailidis","year":"2022","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA Approved for Weight Management in Patients with or Without Diabetes: A Narrative Review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/17446651.2023.2184796","article-title":"An update on tirzepatide for the management of type 2 diabetes: A focus on the phase 3 clinical development program","volume":"18","year":"2023","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management","volume":"32","author":"Sinha","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction","volume":"15","author":"Rizvi","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_17","unstructured":"United States Food and Drug Administration (2022, November 19). FDA News Release. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-dual-targeted-treatment-type-2-diabetes."},{"key":"ref_18","unstructured":"(2022, November 22). European Commission Grants Marketing Authorisation for Lilly\u2019s Mounjaro\u00ae (Tirzepatide), the First GIP and GLP-1 Receptor Agonist for Adults with Type 2 Diabetes in Europe. Available online: https:\/\/www.lillyeu.com\/story\/european-commission-grants-marketing-authorisation-for-lillys-mounjaro-r."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14656566.2023.2192865","article-title":"GLP-1\/GIP analogs: Potential impact in the landscape of obesity pharmacotherapy","volume":"24","author":"Lafferty","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13679-020-00396-9","article-title":"The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity","volume":"9","author":"Koliaki","year":"2020","journal-title":"Curr. Obes. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1053\/j.gastro.2007.03.048","article-title":"Gut hormones and appetite control","volume":"132","author":"Wren","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11892-020-01309-9","article-title":"Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome","volume":"20","author":"Alexiadou","year":"2020","journal-title":"Curr. Diab. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/endrev\/bnab034","article-title":"Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy","volume":"43","author":"Angelidi","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and Glycaemic Outcomes in the LEADER Trial","volume":"9","author":"Zinman","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison with Placebo in Patients With Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108390","DOI":"10.1016\/j.jdiacomp.2022.108390","article-title":"Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review","volume":"37","author":"Liarakos","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/DMSO.S191438","article-title":"Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential","volume":"12","author":"Bastin","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/JOE-20-0119","article-title":"Combination gut hormones: Prospects and questions for the future of obesity and diabetes therapy","volume":"246","author":"Khoo","year":"2020","journal-title":"J. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","article-title":"Unimolecular Polypharmacy for Treatment of Diabetes and Obesity","volume":"24","author":"Finan","year":"2016","journal-title":"Cell Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmet.2017.02.002","article-title":"Monomeric GLP-1\/GIP\/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice","volume":"6","author":"Jall","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2017-00469","article-title":"The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers","volume":"102","author":"Tan","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2014","journal-title":"Mol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/JOE-12-0368","article-title":"Unraveling oxyntomodulin, GLP1\u2019s enigmatic brother","volume":"215","author":"Pocai","year":"2012","journal-title":"J. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.11613\/BM.2017.034","article-title":"Insights on glicentin, a promising peptide of the proglucagon family","volume":"27","author":"Raffort","year":"2017","journal-title":"Biochem. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1210\/clinem\/dgaa061","article-title":"Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss","volume":"105","author":"Nielsen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pelle, M.C., Provenzano, M., Zaffina, I., Pujia, R., Giofr\u00e8, F., Luc\u00e0, S., Andreucci, M., Sciacqua, A., and Arturi, F. (2021). Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)\/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment. Life, 12.","DOI":"10.3390\/life12010029"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a Dual GLP-1R\/GIPR Agonist from Tirzepatide: Comparing Residues between Tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Ajabiya, J., Teli, D., Bojarska, J., and Apostolopoulos, V. (2022). Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 27.","DOI":"10.3390\/molecules27134315"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., and Li, Y. (2023). Weight loss efficiency and safety of tirzepatide: A Systematic review. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285197"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108332","DOI":"10.1016\/j.jdiacomp.2022.108332","article-title":"Tirzepatide: A novel, first-in-class, dual GIP\/GLP-1 receptor agonist","volume":"36","author":"Nuffer","year":"2022","journal-title":"J. Diabetes Complicat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/dmrr.729","article-title":"Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob\/ob) mice: Studies with DPP IV resistant N-AcGIP and exendin(1-39)amide","volume":"23","author":"Irwin","year":"2007","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1042\/CS20110006","article-title":"Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity","volume":"121","author":"Gault","year":"2011","journal-title":"Clin. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bcp.2018.07.021","article-title":"Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential","volume":"155","author":"Pathak","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/dom.13024","article-title":"Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus","volume":"19","author":"Schmitt","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The Sustained Effects of a Dual GIP\/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"bvad056","DOI":"10.1210\/jendso\/bvad056","article-title":"Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)","volume":"7","author":"Lee","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(22)00077-8","article-title":"Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Battelino","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs. Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/dc13-0598","article-title":"Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians","volume":"37","author":"Pedersen","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): A double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): A multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.regpep.2008.11.007","article-title":"Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice","volume":"153","author":"Irwin","year":"2009","journal-title":"Regul. Pept."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., and Persico, M. (2019). NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16183415"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis","volume":"8","author":"Quek","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109981","DOI":"10.1016\/j.diabres.2022.109981","article-title":"Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis","volume":"190","author":"Ciardullo","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease","volume":"33","author":"Moon","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5891532","DOI":"10.1155\/2023\/5891532","article-title":"Research Progress on the GIP\/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes","volume":"2023","author":"Ma","year":"2023","journal-title":"J. Diabetes Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: Insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.14775","article-title":"Efficacy of tirzepatide 5, 10 and 15\u2009mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison","volume":"24","author":"Vadher","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e13543","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes. Rev."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/1875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:04:27Z","timestamp":1760126667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/1875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":76,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["biomedicines11071875"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11071875","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}